| Literature DB >> 30108726 |
Franck Duclos1, Lynn M Abell1, David G Harden1, Kristen Pike1, Kimberly Nowak1, Gregory A Locke1, Gerald J Duke1, Xiaoqin Liu1, Gayani Fernando1, Scott A Shaw1, Benjamin P Vokits1, Nicholas R Wurtz1, Andrew Viet1, Meriah N Valente1, Sylwia Stachura1, Paul Sleph1, Javed A Khan1, Ji Gao1, Ashok R Dongre1, Lei Zhao1, Ruth R Wexler1, David A Gordon1, Ellen K Kick1.
Abstract
Myeloperoxidase, a mammalian peroxidase involved in the immune system as an anti-microbial first responder, can produce hypochlorous acid in response to invading pathogens. Myeloperoxidase has been implicated in several chronic pathological diseases due to the chronic production of hypochlorous acid, as well as other reactive radical species. A high throughput screen and triaging protocol was developed to identify a reversible inhibitor of myeloperoxidase toward the potential treatment of chronic diseases such as atherosclerosis. The identification and characterization of a reversible myeloperoxidase inhibitor, 7-(benzyloxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine is described.Entities:
Year: 2017 PMID： 30108726 PMCID： PMC6071758 DOI： 10.1039/c7md00268h
Source DB: PubMed Journal: Medchemcomm ISSN： 2040-2503 Impact factor: 3.597